Compile Data Set for Download or QSAR
Report error Found 781 with Last Name = 'mckenna' and Initial = 'j'
TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221982(US9303035, 6)
Affinity DataIC50: 0.0500nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221982(US9303035, 6)
Affinity DataIC50: 0.0500nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221986(US9303035, 8.0a)
Affinity DataIC50: 0.0700nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221986(US9303035, 8.0a)
Affinity DataIC50: 0.0700nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221984(US9303035, 7.0a)
Affinity DataIC50: 0.0900nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221984(US9303035, 7.0a)
Affinity DataIC50: 0.0900nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221987(US9303035, 8.1a)
Affinity DataIC50: 0.120nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221987(US9303035, 8.1a)
Affinity DataIC50: 0.120nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMitogen-activated protein kinase 11/12/13/14(Human)
Aventis Pharma

Curated by ChEMBL
LigandPNGBDBM50473625(CHEMBL69319)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of p38-related TNF alpha release by human monocyte cell line (THP-1)More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221983(US9303035, 6.1)
Affinity DataIC50: 0.240nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221983(US9303035, 6.1)
Affinity DataIC50: 0.240nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221992(US9303035, 12.2)
Affinity DataIC50: 0.240nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221992(US9303035, 12.2)
Affinity DataIC50: 0.240nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221989(US9303035, 11a)
Affinity DataIC50: 0.310nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221989(US9303035, 11a)
Affinity DataIC50: 0.310nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221993(US9303035, 12.4)
Affinity DataIC50: 0.540nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221993(US9303035, 12.4)
Affinity DataIC50: 0.540nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221967(US9303035, 2.9)
Affinity DataIC50: 0.590nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221967(US9303035, 2.9)
Affinity DataIC50: 0.590nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221990(US9303035, 12)
Affinity DataIC50: 0.600nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221990(US9303035, 12)
Affinity DataIC50: 0.600nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221985(US9303035, 7.1a)
Affinity DataIC50: 0.610nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221985(US9303035, 7.1a)
Affinity DataIC50: 0.610nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221994(US9303035, 12.5)
Affinity DataIC50: 0.620nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221994(US9303035, 12.5)
Affinity DataIC50: 0.620nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221970(US9303035, 3.2)
Affinity DataIC50: 0.640nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221970(US9303035, 3.2)
Affinity DataIC50: 0.640nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221969(US9303035, 3.1)
Affinity DataIC50: 0.700nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221969(US9303035, 3.1)
Affinity DataIC50: 0.700nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM695278(US12083101, Example 27a)
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

LigandPNGBDBM695279(US12083101, Example 27b)
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

LigandPNGBDBM695310(US12083101, Example 55b | US12083101, Example 55a)
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

LigandPNGBDBM695340(US12083101, Example 71b)
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

LigandPNGBDBM50626283(US12083101, Example 106 | CHEMBL5400107)
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM695385(US12083101, Example 110)
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

LigandPNGBDBM695387(US12083101, Example 112)
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

LigandPNGBDBM695393(US12083101, Example 116a)
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

LigandPNGBDBM695394(US12083101, Example 116b)
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

LigandPNGBDBM695395(US12083101, Example 117a)
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

LigandPNGBDBM695396(US12083101, Example 117b)
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

LigandPNGBDBM695397(US12083101, Example 118)
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

LigandPNGBDBM695431(US12083101, Example 147)
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

LigandPNGBDBM695437(US12083101, Example 153 | 2-((2S,4S)-5-Chloro-6-fl...)
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

LigandPNGBDBM695454(US12083101, Example 170)
Affinity DataIC50: 1nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

LigandPNGBDBM695263(US12083101, Example 12)
Affinity DataIC50: 1.5nMAssay Description:Avi-humanTEAD4217-434 (1 nM, produced as described in Hau et al. ChemBioChem 14, 1218, 2013) and LANCE Eu-W1024 Streptavidin (0.5 nM, PerkinElmer) we...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221952(US9303035, 1.2)
Affinity DataIC50: 1.58nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221952(US9303035, 1.2)
Affinity DataIC50: 1.58nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221958(US9303035, 1.26)
Affinity DataIC50: 1.90nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221958(US9303035, 1.26)
Affinity DataIC50: 1.90nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetCystic fibrosis transmembrane conductance regulator(Chinese hamster)
Novartis

US Patent
LigandPNGBDBM221996(US9303035, 14)
Affinity DataIC50: 1.96nMAssay Description:CFTR activity can be quantified by electrophysiology methods, using the whole-cell configuration of the patch clamp technique (Hamill O, Marty A, Neh...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 781 total ) | Next | Last >>
Jump to: